Optimize the process from trial production to mass production;
Quickly verify the feasibility of scaling up the formula;
Ultra-High Cost Performance;
Scaling trials with 150-200 needles in 2㎡ footprint;
Validate products with low input costs;
Optimize the process from trial production to mass production
Small batch trial production can be conducted first to ensurethat the experimental process and results meet expectationsbefore scaling up, avoiding material waste and time delays.
Quickly verify the feasibility of scaling up the formula
Other equipment: Laboratory data needs continuousre-adjustment to achieve mass production.
MN60: Laboratory data can be directly applied to mass production.saving time and effort.
Ultra-High Cost Performance
The MN60 is available at less than half the cost of traditionaindustrial machine, offering excellent value for its features.
With the cost of a high-end lab machine, you can experiencesmall-scale production.
It allows you to test the market with a low initial investment, andif the product performs well, you can scale up production without tying up significant capital.
Scaling trials with 150-200 needles in 2m footprint
A single MN60 can meet both R&D and small - batch productionneeds, offering flexibility and reliability.
MN60 occupies less than 2㎡,enabling nano -fiber massproduction in small spaces and eliminating the need for costlylarge -space rentals, thus saving millions in potential rental costs.
Validate products with low input costs
MN60 is designed for laboratoray R&D and small volume production, enabling rapid product preparation and market validation.
Key Transition from Single Needle to Multi-Needles
Experimental results from single-needle setups often cannot be directly scaled to production. Traditional laboratory electrospinning machine and industrial-grade electrospinning machine differ greatly in terms of electric field environment, material processing, and other aspects. It creates significant challenges when trying to scale up production, as the production process needs multiple adjustments. The MN60 model bridges the gap, offering an experimental environment that is closer to industrial production.
Avoiding Trial-and-Error Costs in Industrial Upgrades
Upgrading from lab-scale single-needle machine to small industrial-scale machine for higher output requires significant investment. However, MN60 model allows you to validate the scalability of your formulation with minimal investment, helping you avoid the risk of discovering too late that the formula is unsuitable for mass production after committing substantial funds.
